Christine Chung L.
Corporate Officer/Principal chez FIBROGEN, INC.
Fortune : 209 460 $ au 30/04/2024
Postes actifs de Christine Chung L.
Sociétés | Poste | Début | Fin |
---|---|---|---|
FIBROGEN, INC. | Corporate Officer/Principal | 01/01/2007 | - |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Directeur Général | 01/01/2019 | - |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Président | 27/09/2020 | - |
FibroGen International (Hong Kong) Ltd. | Directeur/Membre du Conseil | 01/01/2018 | - |
FibroGen International (Cayman) Ltd. | Directeur/Membre du Conseil | 01/01/2019 | - |
Historique de carrière de Christine Chung L.
Anciens postes connus de Christine Chung L.
Sociétés | Poste | Début | Fin |
---|---|---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Corporate Officer/Principal | - | - |
Formation de Christine Chung L.
Harvard University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Chine | 3 |
Hong Kong | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Technology Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
FIBROGEN, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Technology Services |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Health Technology |
FibroGen International (Hong Kong) Ltd. | |
FibroGen International (Cayman) Ltd. |
- Bourse
- Insiders
- Christine Chung L.
- Expérience